Medicine
Iomervu 163200 mg/200 mL injection
Iomervu 163200 mg/200 mL injection is a prescription medicine containing Iomeprol for intra-arterial, intravenous use, marketed by Bracco Diagnostics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze. Store at 20°C to 25°C (68°F to 77°F). Keep in original carton…
Key facts
- Active ingredient (INN)
- Iomeprol
- Brand
- Iomervu
- Strength
- 163200 mg/200 mL
- Dosage form
- Injection
- Route
- Intra-arterial, intravenous
- Packs
- 10 bottles of 200 mL
- Marketing authorisation holder
- Bracco Diagnostics
- Manufacturer
- Bracco Diagnostics
- Origin register
- US FDA, United States
- Storage
- Do not freeze. Store at 20°C to 25°C (68°F to 77°F). Keep in original carton with the cover closed to protect from light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- V08AB10 Iomeprol
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 January 2026
- Identifiers
- DailyMed set ID cb2e0e00-7c93-0fb4-89a5-861641662a5aNDC 0270-7018Application NDA216016
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 10 bottle, glass in 1 case / 200 mL in 1 bottle, glass | 0270-7018-29 | Bracco Diagnostics | 1 January 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 27 November 2024 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Iomeprol
Clinical summary
Iomeprol is a radiographic contrast agent indicated for intra-arterial Procedures †. Cerebral arteriography, includingintra-arterial digital subtraction angiography (IA-DSA), in adults and pediatric patients Visceral and peripheral arteriography and aortography, including IA-DSA, among other approved uses. MedsAcross supplies Iomeprol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about IomeprolFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- IOMERVU prescribing information (Bracco Diagnostics) · U.S. National Library of Medicine, DailyMed
Need Iomervu 163200 mg/200 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.